相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63)
Craig L. Slingluff et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
A multipeptide vaccine plus toll-like receptor agonists LPS or polylCLC in combination with incomplete Freund's adjuvant in melanoma patients
Marit M. Melssen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Toxicities associated with checkpoint inhibitors-an overview
Laura Spiers et al.
RHEUMATOLOGY (2019)
A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1
Matthew S. Block et al.
MELANOMA RESEARCH (2019)
Activation of human CD141(+) and CD1c(+) dendritic cells in vivo with combined TLR3 and TLR7/8 ligation
Frances E. Pearson et al.
IMMUNOLOGY AND CELL BIOLOGY (2018)
Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies
N. A. Wages et al.
ANNALS OF ONCOLOGY (2017)
Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3
Yong-Chen Lu et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases
Ileana S. Mauldin et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases
Ileana S. Mauldin et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
TLR3 Signaling Promotes the Induction of Unique Human BDCA-3 Dendritic Cell Populations
Nicholas J. Colletti et al.
FRONTIERS IN IMMUNOLOGY (2016)
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8(+) and CD4(+) T-cell responses with multiple specificities including a novel DR7-restricted epitope
P. Baumgaertner et al.
ONCOIMMUNOLOGY (2016)
Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival
Caroline M. Reed et al.
CLINICAL CANCER RESEARCH (2015)
A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma
Nolan A. Wages et al.
CONTEMPORARY CLINICAL TRIALS (2015)
Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma
Rachel Lubong Sabado et al.
CANCER IMMUNOLOGY RESEARCH (2015)
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Paul F. Robbins et al.
CLINICAL CANCER RESEARCH (2015)
Inflammatory Adverse Events are Associated with Disease-Free Survival after Vaccine Therapy among Patients with Melanoma
Yinin Hu et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells
Moonkyu Lee et al.
ARCHIVES OF PHARMACAL RESEARCH (2014)
Targeting Uptake Receptors on Human Plasmacytoid Dendritic Cells Triggers Antigen Cross-Presentation and Robust Type I IFN Secretion
Jurjen Tel et al.
JOURNAL OF IMMUNOLOGY (2013)
Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion
Yared Hailemichael et al.
NATURE MEDICINE (2013)
Clinical Adjuvant Combinations Stimulate Potent B-Cell Responses In Vitro by Activating Dermal Dendritic Cells
Katie Matthews et al.
PLOS ONE (2013)
Peptide Vaccination in Montanide Adjuvant Induces and GM-CSF Increases CXCR3 and Cutaneous Lymphocyte Antigen Expression by Tumor Antigen-Specific CD8 T Cells
Eleanor Clancy-Thompson et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
Paul Sabbatini et al.
CLINICAL CANCER RESEARCH (2012)
The Vaccine-site Microenvironment Induced by Injection of Incomplete Freund's Adjuvant, With or Without Melanoma Peptides
Rebecca C. Harris et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Dose-finding design for multi-drug combinations
Nolan A. Wages et al.
CLINICAL TRIALS (2011)
Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine
Craig L. Slingluff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function
Walter C. Olson et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Douglas J. Schwartzentruber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis
Jochen T. Schaefer et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial
Craig L. Slingluff et al.
CLINICAL CANCER RESEARCH (2009)
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia.
Gemma G. Kenter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Topical resiquimod promotes priming of CTL to parenteral antigens
Brent A. Chang et al.
VACCINE (2009)
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines
Cory L. Ahonen et al.
BLOOD (2008)
Treatment of metastatic melanoma with autologous CD4+T cells against NY-ESO-1
Naomi N. Hunder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Immunologic and clinical outcomes of a Randomized phase II trial of two multipeptide Vaccines for melanoma in the adjuvant setting
Craig L. Slingluff et al.
CLINICAL CANCER RESEARCH (2007)
CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity
Martijn S. Bijker et al.
JOURNAL OF IMMUNOLOGY (2007)
Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo
Phillip J. Sanchez et al.
JOURNAL OF IMMUNOLOGY (2007)
Cutting edge: Activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides
Keith K. B. Gorden et al.
JOURNAL OF IMMUNOLOGY (2006)
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909
DE Speiser et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
A listing of human tumor antigens recognized by T cells: March 2004 update
L Novellino et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule
CL Slingluff et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
分享论文
